Loading news...
Asia-Pacific equities outside Japan have quietly delivered one of the stronger performances among developed-market ETFs over the past year, and most retirees haven't noticed.
JPMorgan Chase and Co. cut its stake in iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,912,109 shares of the company's stock after selling 197,114 shares during the quarter. JPMorgan
WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced that the U.S. Food and Drug Administration (FDA) today issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for bitopertin as a treatment for patients with erythropoietic protoporphyria (EPP). Bitopertin has been under review for accelerated approval and as part of the Commissioner's National Priority Voucher (CNPV) pilot program.
Shares of iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP - Get Free Report) reached a new 52-week high during mid-day trading on Friday. The company traded as high as $52.77 and last traded at $52.7450, with a volume of 56324 shares. The stock had previously closed at $52.38. iShares MSCI Pacific ex Japan ETF
The European Commission on Tuesday will propose rule changes that reverse previous plans for an effective ban on selling new cars with combustion engines in the 27-nation bloc from 2035, a senior EU lawmaker said on Friday.
SP Angel's take on EnergyPathways PLC (AIM:EPP) is that the company has landed an important early-stage partner. The £12 million developer has signed a non-binding cooperation agreement with Siemens Energy covering long-duration energy storage, specifically compressed air systems that can soak up excess wind power and release it when needed.
EnergyPathways PLC (AIM:EPP) shares jumped as much as 10% on Wednesday after the company unveiled a partnership with Siemens Energy to develop long-duration energy storage aimed at helping the grid cope with the swings of renewable generation. The AIM-quoted group has signed a non-binding cooperation agreement with the German engineering giant to advance Compressed Air Energy Storage, a technology that uses surplus power to force air into underground caverns, releasing it later to drive turbines when demand is higher.
EnergyPathways PLC (AIM:EPP) has teamed up with Siemens Energy to explore a new generation of long-duration energy storage that could help smooth out the peaks and troughs of renewable power. The company, which is listed on London's junior AIM market, said it had signed a non-binding cooperation agreement with the German engineering group to work on Compressed Air Energy Storage, a system that stores surplus electricity by using it to compress air underground.
WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted the NDA under the FDA's accelerated approval pathway using reduction of protoporphyrin IX (PPIX) as a surrogate endpoint and requested a Priority Review based on bitopertin's potential to address the significant unmet need for EPP patients. Bitopertin has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.
EnergyPathways PLC (AIM:EPP) CEO Ben Clube talked with Proactive about a new collaboration with Siemens Energy to advance the MESH integrated energy storage project. This marks a significant milestone for the company as Siemens Energy begins feasibility and engineering design work focused on long-duration energy storage and compressed air storage components.
Shares in EnergyPathways PLC (AIM:EPP) soared as much as 53% in afternoon trading on Monday after the company revealed Siemens Energy will lead a feasibility study for its flagship MESH energy storage project. The MESH project aims to combine offshore hydrogen, compressed air, and gas storage, delivering low- or zero-carbon electricity to the UK grid and enhancing the country's energy flexibility.
EnergyPathways PLC (AIM:EPP) has taken a significant step in its drive to become a leader in grid-scale energy storage, announcing Siemens Energy will conduct a feasibility assessment for its flagship MESH project. MESH aims to integrate offshore hydrogen, compressed air, and gas storage to deliver low- to zero-carbon power to the UK grid, supporting the transition to a renewables-driven energy system.
The iShares MSCI Pacific Ex. Japan ETF (EPP) invests in over 90 companies in developed Pacific markets, excluding Japan, with a 0.48% management fee. This ETF offers a 3.7% dividend yield and lower valuation, making it a safer option against potential sell-offs in growth and tech stocks in 2025-2026. The ETF primarily tracks the MSCI Pacific Ex. Japan Index, heavily weighted in banking, materials, and industrials, which constitute over 60% of the index.
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the APOLLO post-marketing confirmatory trial for bitopertin in EPP.
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST.
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting the regulatory path forward for bitopertin in EPP.
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST.
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). If approved, SCENESSE® would be the first treatment for Canadian EPP patients.
Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024. Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024.